Language biomarker screening using AI: a transdiagnostic approach to the brain

Individuals with left-hemisphere damage (LHD), right-hemisphere damage (RHD), dementia, mild cognitive impairment (MCI), traumatic brain injury (TBI), and healthy controls are characterized by overlapping clinical profiles affecting communication and social interaction. Language provides a rich, non-invasive window into neurological health, yet objective and scalable methods to automatically differentiate between conditions with are lacking. This method aims to develop comprehensive neurolinguistic measures of these conditions, develop a machine learning multiclass screening and language assessment model (NeuroScreen) and offer a large comparative database of measures for other studies to build upon. We combined one of the largest databases, comprising 291 linguistic biomarkers calculated from speech samples produced by 1,394 participants: 536 individuals with aphasia secondary to LHD, 193 individuals with dementia, 107 individuals with MCI, 38 individuals with RHD, 58 individuals with TBI, and 498 Healthy Controls. Employing natural language processing (NLP) via the Open Brain AI platform ( http://openbrainai.com ), we extracted multiple linguistic features from the speech samples, including readability, lexical richness, phonology, morphology, syntax, and semantics. A Deep Neural Network architecture (DNN) classifies these conditions from linguistic features with high accuracy (up to 91%). A linear mixed-effects model approach was employed to determine the biomarkers of the neurological conditions, revealing distinct, quantitative neurolinguistic properties: LHD and TBI show widespread deficits in syntax and phonology; MCI is characterized by fine-grained simplification; patients with dementia present with specific lexico-semantic impairments; and RHD shows the most preserved profile. Ultimately, the outcomes provide an automatic detection and classification model of key neurological conditions affecting language, along with a novel set of validated neurological markers for facilitating differential diagnosis, remote monitoring, and personalized neurological care.